BERLIN and SEATTLE, Oct. 4, 2007 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (ISIN: DE000A0BVT96) today announced that key patents covering Epigenomics’ core technology HeavyMethyl(r) for the sensitive detection of methylated DNA have been granted by the patent authorities in a wide range of market regions including Europe (Patent EP 1 370 691) and the U.S. (Patent U.S. 7,229,759).
